Hainan Shuangcheng Pharmaceuticals Co., Ltd.
Símbolo: 002693.SZ
SHZ
5.69
CNYPrecio de mercado actual
-39.5632
Ratio PER
2.2749
Ratio PEG
2.36B
Capitalización MRK
- 0.00%
Rendimiento DIV
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 291.41 | 31.9 | 146 | 77 | |||||||||||||||
balance-sheet.row.short-term-investments | 223.27 | 28.5 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.net-receivables | 97.01 | 16.4 | 41 | 33.1 | |||||||||||||||
balance-sheet.row.inventory | 306.61 | 74.3 | 65.4 | 55.2 | |||||||||||||||
balance-sheet.row.other-current-assets | 0.25 | 0.2 | 0 | 0.1 | |||||||||||||||
balance-sheet.row.total-current-assets | 721.6 | 135.2 | 252.4 | 165.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1823.92 | 457.6 | 471.8 | 504.7 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 688.05 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 688.05 | 171.8 | 164.9 | 156.9 | |||||||||||||||
balance-sheet.row.long-term-investments | 44.81 | 10 | 8.8 | 17.3 | |||||||||||||||
balance-sheet.row.tax-assets | 4.76 | 1.5 | 1 | 1 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 83.17 | 27.1 | 12.2 | 9.1 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 2644.71 | 668 | 658.6 | 689.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 3366.32 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.account-payables | 61.58 | 17.1 | 15.5 | 17.2 | |||||||||||||||
balance-sheet.row.short-term-debt | 388.3 | 10.1 | 205.3 | 0.3 | |||||||||||||||
balance-sheet.row.tax-payables | 13.4 | 3.7 | 12.8 | 7.2 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 290.02 | 135 | 0 | 167 | |||||||||||||||
Deferred Revenue Non Current | 31.26 | 8 | 7.6 | 8.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 11.26 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 9.06 | 2 | 73.6 | 1.8 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 332.55 | 145.7 | 10.7 | 179.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 1177.06 | 285.6 | 330.1 | 287.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 68.85 | 34.4 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 1666.33 | 416.7 | 414.7 | 412 | |||||||||||||||
balance-sheet.row.retained-earnings | -1287.93 | -347 | -296.2 | -305.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 501.27 | -0.4 | 87.2 | 82.2 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1044.52 | 367.6 | 307.9 | 292.9 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 1993.04 | 471.5 | 513.5 | 481.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 3366.32 | 803.2 | 911 | 854.6 | |||||||||||||||
balance-sheet.row.minority-interest | 196.22 | 46.2 | 67.4 | 84.9 | |||||||||||||||
balance-sheet.row.total-equity | 2189.26 | 517.6 | 580.9 | 566.8 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 3366.32 | - | - | - | |||||||||||||||
Total Investments | 206.63 | 10 | 133.8 | 55.4 | |||||||||||||||
balance-sheet.row.total-debt | 678.32 | 145.1 | 205.3 | 167.3 | |||||||||||||||
balance-sheet.row.net-debt | 610.18 | 141.7 | 193.1 | 145.6 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -63.99 | -8.5 | -40.8 | -79.9 | ||||||||||||||
cash-flows.row.depreciation-and-amortization | 40.38 | 57.5 | 54.3 | 57.1 | ||||||||||||||
cash-flows.row.deferred-income-tax | -3.82 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.stock-based-compensation | 1.42 | 6.9 | 7.2 | -1.2 | ||||||||||||||
cash-flows.row.change-in-working-capital | -10.62 | -4.5 | 14.9 | -12.2 | ||||||||||||||
cash-flows.row.account-receivables | 4.99 | -13.8 | 5.4 | 39.8 | ||||||||||||||
cash-flows.row.inventory | -12.45 | -9.9 | -4.8 | -4.3 | ||||||||||||||
cash-flows.row.account-payables | 0 | 19.6 | 13.8 | -48.9 | ||||||||||||||
cash-flows.row.other-working-capital | -3.17 | -0.4 | 0.4 | 1.2 | ||||||||||||||
cash-flows.row.other-non-cash-items | 45.94 | -25.8 | -12.5 | 24.5 | ||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.88 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.acquisitions-net | 14.27 | 27 | 21.7 | 53.6 | ||||||||||||||
cash-flows.row.purchases-of-investments | -193.85 | -471 | -256.2 | -637.2 | ||||||||||||||
cash-flows.row.sales-maturities-of-investments | 263.71 | 391.9 | 299.2 | 615.3 | ||||||||||||||
cash-flows.row.other-investing-activites | 13.08 | 0 | 0 | -51.6 | ||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 16.89 | -85.1 | 33 | -71.5 | ||||||||||||||
cash-flows.row.debt-repayment | -92.11 | -12 | -55.3 | -1.8 | ||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||
cash-flows.row.dividends-paid | -7.78 | -11.1 | -9.1 | -9.8 | ||||||||||||||
cash-flows.row.other-financing-activites | 35.64 | 68.1 | 23.8 | 57 | ||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -13.02 | 44.9 | -40.6 | 45.4 | ||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.01 | 0.1 | -0.1 | -0.3 | ||||||||||||||
cash-flows.row.net-change-in-cash | 11.76 | -14.8 | 15.8 | -36.9 | ||||||||||||||
cash-flows.row.cash-at-end-of-period | 68.14 | 6.8 | 21.6 | 5.8 | ||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 56.38 | 21.6 | 5.8 | 42.7 | ||||||||||||||
cash-flows.row.operating-cash-flow | 7.88 | 25.2 | 23.6 | -10.5 | ||||||||||||||
cash-flows.row.capital-expenditure | -50.56 | -33 | -31.6 | -51.6 | ||||||||||||||
cash-flows.row.free-cash-flow | -42.68 | -7.8 | -8.1 | -62.1 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 197.21 | 235.9 | 274.8 | 320.3 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 68.14 | 74.9 | 88.3 | 81.4 | |||||||||||||||
income-statement-row.row.gross-profit | 129.06 | 161.1 | 186.5 | 238.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 8.41 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 20.73 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.19 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.operating-expenses | 164.04 | 183.4 | 215.8 | 282.7 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 232.18 | 258.3 | 304.1 | 364.1 | |||||||||||||||
income-statement-row.row.interest-income | 0.04 | 0 | 0.1 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 9.04 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 80.37 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -58.06 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.19 | 0.2 | 63.2 | 69 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -58.06 | -50.6 | 15.6 | 2 | |||||||||||||||
income-statement-row.row.interest-expense | 9.04 | 9.6 | 11.2 | 9 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 32.98 | 52.7 | 57.5 | 54.3 | |||||||||||||||
income-statement-row.row.ebitda-caps | -31.85 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | -87.45 | -73.2 | -24.5 | -42.3 | |||||||||||||||
income-statement-row.row.income-before-tax | -87.26 | -73 | -8.9 | -40.4 | |||||||||||||||
income-statement-row.row.income-tax-expense | -12.63 | -1 | -0.4 | 0.4 | |||||||||||||||
income-statement-row.row.net-income | -63.99 | -50.7 | -8.5 | -40.8 |
Preguntas frecuentes
Cuánto es Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) activos totales?
Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) los activos totales son 803248121.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son 96442813.000.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.654.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -0.103.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es -0.324.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son -0.443.
¿Qué es Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es -50741578.370.
¿Cuál es la deuda total de la empresa?
La deuda total es 145050750.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 183423820.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 17684279.000.